ETR 028
Alternative Names: ETR-028Latest Information Update: 08 Mar 2024
At a glance
- Originator Elysium Therapeutics
- Class Antitussives; Morphinans; Opioid analgesics; Opioid peptides; Small molecules
- Mechanism of Action Opioid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Pain
Most Recent Events
- 06 Mar 2024 Interim efficacy, adverse events and pharmacokinetic data from a phase I trial in Pain released by Elysium Therapeutics
- 27 Sep 2022 Phase-I clinical trials in Pain (In volunteers) in USA (PO) (NCT05572190)
- 07 Nov 2017 Elysium Therapeutics has patent protection for the polysubunit opioid prodrugs resistant to overdose in USA